Deactivation (τw, deact, ms) | Desensitization (τw, des, ms) | Steady-state current (% peak) | |
---|---|---|---|
GluA1 | 1.3 ± 0.2 (10) | 2.6 ± 0.1 (22) | 1.9 ± 0.3 (22) |
+CNIH-1 | 1.0 ± 0.2 (6)# | 2.3 ± 0.1 (6) | 1.9 ± 1.1 (6) |
+CNIH-2 | 4.0 ± 0.8 (10)* | 5.5 ± 0.6 (15)***,# | 6.7 ± 2.3 (15) |
+CNIH-3 | 3.3 ± 0.6 (14)* | 5.0 ± 0.6 (10)*** | 4.1 ± 1.4 (10) |
+γ-2 | 2.1 ± 0.2 (11)* | 3.9 ± 0.2 (20)*** | 3.6 ± 0.5 (20)* |
GluA1/A2(R) | 0.8 ± 0.1 (5) | 5.5 ± 0.3 (13) | 3.8 ± 0.7 (13) |
+CNIH-2 | — | 14.1 ± 3.7 (6)* | 15.2 ± 5.2 (6)** |
+CNIH-3 | 1.3 ± 0.1 (10)** | 10.9 ± 1.9 (10)*** | 13.2 ± 3.2 (10)** |
+γ-2 | — | 7.7 ± 0.5 (12)* | 20.4 ± 2.4 (12)*** |
GluA2(Q) | 1.0 ± 0.2 (11) | 5.0 ± 0.2 (25) | 1.8 ± 0.2 (25) |
+CNIH-2 | — | 12.1 ± 1.4 (9)*** | 8.9 ± 2.4 (9)* |
+CNIH-3 | 12.3 ± 4.5 (6)** | 25.5 ± 3.7 (12)***,### | 11.3 ± 2.4 (12)*** |
+γ-2 | — | 10.2 ± 1.0 (12)*** | 6.7 ± 1.5 (12)** |
Values are mean ± SEM (n). Tests of differences among group data were performed using a Kruskal–Wallis rank-sum test followed by pairwise Wilcoxon rank-sum tests with Holm's sequential Bonferroni correction. Statistical significance of single comparisons [GluA2(Q) and GluA1/A2 deactivation] was determined using a Wilcoxon rank-sum test.
↵*p < 0.05,
↵**p < 0.01,
↵***p < 0.001 compared with AMPAR alone.
↵#p < 0.05,
↵###p < 0.001 compared with +γ-2 condition.